These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 24363397)

  • 21. Anti‑survival and pro‑apoptotic effects of meridianin C derivatives on MV4‑11 human acute myeloid leukemia cells.
    Cho H; Yadav AK; Do Y; Heo M; Bishop-Bailey D; Lee J; Jang BC
    Int J Oncol; 2020 Jan; 56(1):368-378. PubMed ID: 31789392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.
    Meja K; Stengel C; Sellar R; Huszar D; Davies BR; Gale RE; Linch DC; Khwaja A
    Br J Haematol; 2014 Oct; 167(1):69-79. PubMed ID: 24975213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase.
    Fathi AT; Arowojolu O; Swinnen I; Sato T; Rajkhowa T; Small D; Marmsater F; Robinson JE; Gross SD; Martinson M; Allen S; Kallan NC; Levis M
    Leuk Res; 2012 Feb; 36(2):224-31. PubMed ID: 21802138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia.
    Bjørnstad R; Aesoy R; Bruserud Ø; Brenner AK; Giraud F; Dowling TH; Gausdal G; Moreau P; Døskeland SO; Anizon F; Herfindal L
    Mol Cancer Ther; 2019 Mar; 18(3):567-578. PubMed ID: 30679386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIM kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cellsin vitrowhile also maximizing suppression of tumor growthin vivo when combined with immunotherapy.
    Anwar A; Lepore C; Czerniecki BJ; Koski GK; Showalter LE
    Cell Immunol; 2024; 397-398():104805. PubMed ID: 38244265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin receptor substrate 1 is a substrate of the Pim protein kinases.
    Song JH; Padi SK; Luevano LA; Minden MD; DeAngelo DJ; Hardiman G; Ball LE; Warfel NA; Kraft AS
    Oncotarget; 2016 Apr; 7(15):20152-65. PubMed ID: 26956053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells.
    Beharry Z; Zemskova M; Mahajan S; Zhang F; Ma J; Xia Z; Lilly M; Smith CD; Kraft AS
    Mol Cancer Ther; 2009 Jun; 8(6):1473-83. PubMed ID: 19509254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
    Glitscher M; Benz NI; Sabino C; Murra RO; Hein S; Zahn T; Mhedhbi I; Stefanova D; Bender D; Werner S; Hildt E
    Antiviral Res; 2024 Jun; 226():105891. PubMed ID: 38649071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
    Kreuz S; Holmes KB; Tooze RM; Lefevre PF
    Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
    Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J; Francesch-Domenech E; Plumb DA; Zakka L; Gazinska P; Liccardi G; Meier P; Gris-Oliver A; Cheang MC; Perdrix-Rosell A; Shafat M; Noël E; Patel N; McEachern K; Scaltriti M; Castel P; Noor F; Buus R; Mathew S; Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN
    Nat Med; 2016 Nov; 22(11):1303-1313. PubMed ID: 27775704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.
    Scarpa M; Singh P; Bailey CM; Lee JK; Kapoor S; Lapidus RG; Niyongere S; Sangodkar J; Wang Y; Perrotti D; Narla G; Baer MR
    Mol Cancer Ther; 2021 Apr; 20(4):676-690. PubMed ID: 33568357
    [No Abstract]   [Full Text] [Related]  

  • 32. Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication.
    Natarajan K; Xie Y; Burcu M; Linn DE; Qiu Y; Baer MR
    PLoS One; 2013; 8(9):e74653. PubMed ID: 24040307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell-Specific Computational Modeling of the PIM Pathway in Acute Myeloid Leukemia.
    Silverbush D; Grosskurth S; Wang D; Powell F; Gottgens B; Dry J; Fisher J
    Cancer Res; 2017 Feb; 77(4):827-838. PubMed ID: 27965317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
    Chatterjee S; Chakraborty P; Daenthanasanmak A; Iamsawat S; Andrejeva G; Luevano LA; Wolf M; Baliga U; Krieg C; Beeson CC; Mehrotra M; Hill EG; Rathmell JC; Yu XZ; Kraft AS; Mehrotra S
    Clin Cancer Res; 2019 Feb; 25(3):1036-1049. PubMed ID: 30327305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RNA-Seq analysis reveals that spring viraemia of carp virus induces a broad spectrum of PIM kinases in zebrafish kidney that promote viral entry.
    Pereiro P; Álvarez-Rodríguez M; Valenzuela-Muñoz V; Gallardo-Escárate C; Figueras A; Novoa B
    Fish Shellfish Immunol; 2020 Apr; 99():86-98. PubMed ID: 32004617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
    Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
    Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
    Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
    PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
    Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.
    Cen B; Xiong Y; Song JH; Mahajan S; DuPont R; McEachern K; DeAngelo DJ; Cortes JE; Minden MD; Ebens A; Mims A; LaRue AC; Kraft AS
    Mol Cell Biol; 2014 Jul; 34(13):2517-32. PubMed ID: 24777602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.